Sort   by:  
 Page size 
UnknownPertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data.
Not available
S-EPMC10656527 | biostudies-literature
UnknownValidation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillance.
Not available
S-EPMC11550521 | biostudies-literature
UnknownMolecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases.
Not available
S-EPMC6497554 | biostudies-literature
UnknownPertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study.
Not available
S-EPMC8376355 | biostudies-literature
UnknownPersistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.
Not available
S-EPMC3138635 | biostudies-literature
UnknownLongitudinal trajectories of treatment burden: A prospective survey study of adults living with multiple chronic conditions in the midwestern United States.
Not available
S-EPMC9106306 | biostudies-literature
UnknownRandomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.
Not available
S-EPMC6085179 | biostudies-literature
UnknownProspective Study of Psychosocial Outcomes of Having Contralateral Prophylactic Mastectomy Among Women With Nonhereditary Breast Cancer.
Not available
S-EPMC6118404 | biostudies-literature
UnknownIntense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.
Not available
S-EPMC4226804 | biostudies-literature
UnknownEffects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone.
Not available
S-EPMC3295561 | biostudies-literature
Sort   by:  
 Page size